Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Applied Therapeutics Inc (DE:2UV)
FRANKFURT:2UV
Holding DE:2UV?
Track your performance easily
2UV Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.65 - €9.45
Previous Close€9.18
Volume0.00
Average Volume (3M)1.17K
Market Cap
€1.08B
Enterprise Value€993.00M
Total Cash (Recent Filing)$98.90M
Total Debt (Recent Filing)$1.97M
Price to Earnings (P/E)―
Beta-0.61
Next Earnings
Mar 14, 2025EPS Estimate
-€0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding116,356,474
10 Day Avg. Volume260
30 Day Avg. Volume1,169
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)183.60
Price to Sales (P/S)119.23
Price to Cash Flow (P/CF)-12.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.71K
Enterprise Value/Gross Profit99.37
Enterprise Value/Ebitda-5.14
Forecast
1Y Price Target
€12.00Price Target Upside30.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Applied Therapeutics News
PremiumCompany Announcements
Applied Therapeutics Advances with Govorestat ApprovalsBulls Say, Bears Say
Bulls Say
Market OpportunityThe potential govorestat launch in galactosemia and sorbitol dehydrogenase (SORD) deficiency is seen as an opportunity for investors.
Regulatory ProgressThe FDA no longer requires an advisory committee meeting for govorestat in patients with galactosemia, increasing confidence in the drug's approval.
Stock PerformanceAPLT stock traded up approximately 69% on the recent news of the Adcom cancellation, indicating strong investor confidence.
Bears Say
FDA Approval ConcernsRecent weakness, Wall Street chatter, and options activity suggest that some investors are still betting against an approval for govorestat in galactosemia.
Financial PerformanceFor third quarter 2024, Applied reported a net loss of $68.6 million.
Pipeline ChangesThe company has removed the diabetic peripheral neuropathy indication for AT-001 from its pipeline chart.
---
Options Prices
Currently, No data available
---
Ownership Overview
14.39% Insiders
9.99% Mutual Funds
3.45% Other Institutional Investors
54.36% Public Companies and
Individual Investors
2UV FAQ
What was Applied Therapeutics Inc’s price range in the past 12 months?
Applied Therapeutics Inc lowest stock price was €1.65 and its highest was €9.45 in the past 12 months.
What is Applied Therapeutics Inc’s market cap?
Currently, no data Available
When is Applied Therapeutics Inc’s upcoming earnings report date?
Applied Therapeutics Inc’s upcoming earnings report date is Mar 14, 2025 which is in 120 days.
How were Applied Therapeutics Inc’s earnings last quarter?
Applied Therapeutics Inc released its earnings results on Nov 07, 2024. The company reported -€0.452 earnings per share for the quarter, missing the consensus estimate of -€0.149 by -€0.303.
Is Applied Therapeutics Inc overvalued?
According to Wall Street analysts Applied Therapeutics Inc’s price is currently Undervalued.
Does Applied Therapeutics Inc pay dividends?
Applied Therapeutics Inc does not currently pay dividends.
What is Applied Therapeutics Inc’s EPS estimate?
Applied Therapeutics Inc’s EPS estimate is -€0.17.
How many shares outstanding does Applied Therapeutics Inc have?
Applied Therapeutics Inc has 116,356,476 shares outstanding.
What happened to Applied Therapeutics Inc’s price movement after its last earnings report?
Applied Therapeutics Inc reported an EPS of -€0.452 in its last earnings report, missing expectations of -€0.149. Following the earnings report the stock price went down -2.93%.
Which hedge fund is a major shareholder of Applied Therapeutics Inc?
Among the largest hedge funds holding Applied Therapeutics Inc’s share is Perceptive Advisors LLC. It holds Applied Therapeutics Inc’s shares valued at 37M.
---
Applied Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€12.00 (30.70% Upside)
€12.00 (30.70% Upside)
Blogger Sentiment
Bullish
DE:2UV Sentiment 75%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $4.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
387.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
135.79%
Trailing 12-Months
Company Description
Applied Therapeutics Inc
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
---
2UV Stock 12 Month Forecast
Average Price Target
€12.00
▲(30.70% Upside)
Technical Analysis
Applied Therapeutics
―
AlloVir
―
Bicycle Therapeutics
―
Corvus Pharmaceuticals
―
Galera Therapeutics
―
Best Analysts Covering 2UV
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+72.99%
reiterated a buy rating 2 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +72.99% per trade.
---